9 C.F.R. § 113.203 Feline Panleukopenia Vaccine, Killed Virus.
Title 9 - Animals and Animal Products
Feline Panleukopenia Vaccine, Killed Virus, shall be prepared from virus-bearing cell culture fluids. Only Master Seed which has been established as pure, safe, and immunogenic shall be used for preparing seeds for vaccine production. All serials of vaccine shall be prepared from the first through the fifth passage from the Master Seed. The Master Seed shall meet the applicable requirements prescribed in §113.200. Each serial shall meet the applicable general requirements prescribed in §113.200 and the special requirements for safety and potency provided in this section. (a) Safety test. The vaccinates used in the potency test in paragraph (b) of this section shall be observed each day during the postvaccination observation period. If unfavorable reactions occur which are attributable to the vaccine, the serial is unsatisfactory. If unfavorable reactions occur which are not attributable to the vaccine, the test is inconclusive and may be repeated: Provided, That, if not repeated, the serial is unsatisfactory. (b) Potency test—serum-neutralization test. Bulk or final container samples of completed product shall be tested for potency using five susceptible cats (four vaccinates and one control) as the test animals. Blood samples drawn from each cat shall be individually tested for neutralizing antibody against feline panleukopenia virus to determine susceptibility. (1) A constant virus-varying serum neutralization test in tissue culture using 100 to 300 TCID50 of virus shall be used. Cats shall be considered susceptible if there is no neutralization at a 1:2 final serum dilution. (2) Vaccination. Each of the four vaccinates shall be injected as recommended on the label. If two doses are recommended, the second dose shall be given 7 to 10 days after the first dose and the cats observed each day for 14 to 21 days. (3) Serology. At the end of the postvaccination observation period, a second blood sample shall be obtained from each of the five cats and the serums shall be individually tested for neutralizing antibody against feline panleukopenia virus in the same manner used to determine susceptibility. (4) Interpretation of the SN test. (i) If the control has not remained seronegative at 1:2, the test is inconclusive and may be repeated. (ii) If at least 3 of the 4 vaccinates in a valid test have not developed titers based upon final serum dilution of at least 1:8, and the remaining vaccinate has not developed a titer of at least 1:4, the serial is unsatisfactory except as provided in paragraphs (b)(5) and (6) of this section. (5) Virus-challenge test. If the results of a valid SN test are unsatisfactory, the vaccinates and the control may be challenged with a virulent feline panleukopenia virus furnished by Veterinary Services and each animal observed each day for an additional 14 days. (6) Interpretation of the virus-challenge test. If the control does not show clinical signs of feline panleukopenia, the test is inconclusive and may be repeated except, that if any of the vaccinates show such signs, the serial is unsatisfactory. Clinical signs of feline panleukopenia shall include a pronounced leukopenia wherein the white blood cell count drops to 4,000 or less per cubic mm or the white cell count drops to less than 25 percent of the normal level established by an average of three or more counts taken prior to challenge. [39 FR 27428, July 29, 1974, as amended at 40 FR 759, Jan. 3, 1975; 43 FR 41186, Sept. 15, 1978; 43 FR 50162, Oct. 27, 1978; 50 FR 23796, June 6, 1985. Redesignated at 55 FR 35562, Aug. 31, 1990, as amended at 56 FR 66786, Dec. 26, 1991]
Title 9: Animals and Animal Products
PART 113—STANDARD REQUIREMENTS
Killed Virus Vaccines
§ 113.203 Feline Panleukopenia Vaccine, Killed Virus.
